Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15379963 | 0.91 | OPRL1 (0.32) | — | |
| SCHEMBL15380359 | 0.91 | OPRL1 (0.35) | — | |
| SCHEMBL15379918 | 0.89 | OPRL1 (0.37) | — | |
| SCHEMBL15380715 | 0.80 | OPRL1 (0.34) | — | |
| SCHEMBL15380710 | 0.80 | OPRM1 (0.31) | — | |
| SCHEMBL15379849 | 0.79 | OPRL1 (0.36) | — | |
| SCHEMBL14350391 | 0.63 | — | — | |
| SCHEMBL791484 | 0.62 | — | — | |
| SCHEMBL6753128 | 0.57 | — | — | |
| SCHEMBL8781639 | 0.57 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441726-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-20230145003-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230145003-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230145003-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| EP-4096667-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| WO-2021155320-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| US-10383880-B2 | Carbazole-containing sulfonamides as cryptochrome modulators | Synchronicity (US) | 2019-08-20 | — | — | US | disclosed |
| EP-2855458-B1 | CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS | RESET THERAPEUTICS INC (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-2855458-B1 | CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS | RESET THERAPEUTICS INC (US) | 2018-08-08 | — | — | EP | disclosed |
| US-20180071306-A1 | CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. | 2018-03-15 | — | — | US | disclosed |
| US-20130303524-A1 | Carbazole-Containing Sulfonamides as Cryptochrome Modulators | Synchronicity Pharma, Inc. | 2013-11-14 | — | — | US | disclosed |
| US-20130303524-A1 | Carbazole-Containing Sulfonamides as Cryptochrome Modulators | Synchronicity Pharma, Inc. | 2013-11-14 | — | — | US | disclosed |
| US-7772262-B2 | Substituted benzoylguanidines, method for production and use thereof as medicament or diagnostic and medicament comprising the same | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-08-10 | — | — | US | disclosed |
| US-7772262-B2 | Substituted benzoylguanidines, method for production and use thereof as medicament or diagnostic and medicament comprising the same | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-08-10 | — | — | US | disclosed |
| US-7772262-B2 | Substituted benzoylguanidines, method for production and use thereof as medicament or diagnostic and medicament comprising the same | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-08-10 | — | — | US | disclosed |
| EP-1812412-B1 | SUBSTITUTED BENZOYLGUANIDINES METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT OR DIAGNOSTIC AND MEDICAMENT COMPRISING THE SAME | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-04-23 | — | — | EP | disclosed |
| US-20070270414-A1 | SUBSTITUTED BENZOYLGUANIDINES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT OR DIAGNOSTIC AND MEDICAMENT COMPRISING THE SAME | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-11-22 | — | — | US | disclosed |
| US-20070270414-A1 | SUBSTITUTED BENZOYLGUANIDINES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT OR DIAGNOSTIC AND MEDICAMENT COMPRISING THE SAME | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-11-22 | — | — | US | disclosed |
| US-20070270414-A1 | SUBSTITUTED BENZOYLGUANIDINES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT OR DIAGNOSTIC AND MEDICAMENT COMPRISING THE SAME | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-11-22 | — | — | US | disclosed |
| WO-2006050830-A1 | SUBSTITUTED BENZOYLGUANIDINES METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT OR DIAGNOSTIC AND MEDICAMENT COMPRISING THE SAME | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303524-A1 | Carbazole-Containing Sulfonamides as Cryptochrome Modulators | CRY1, CRY2, CRYAB | GRIA2 2370/4885 |
| US-10383880-B2 | Carbazole-containing sulfonamides as cryptochrome modulators | CRY1, CRY2, CRYAB | GRIA2 2108/4885 |
| US-12441726-B2 | Compounds and uses thereof | VHL, CLN6, TFEB | GRIA2 3121/4885 |
| US-20070270414-A1 | SUBSTITUTED BENZOYLGUANIDINES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT OR DIAGNOSTIC AND MEDICAMENT COMPRISING THE SAME | SLC9A1, SLC9B2, SLC9A2 | GRIA2 1427/4885 |
| US-20230145003-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | GRIA2 3121/4885 |
| US-20180071306-A1 | CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS | CRY1, CRY2, CRYAB | GRIA2 2108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.